NASDAQ · AIMD
Healthcare · Biotechnology
$1.42
Down-$0.02 (-1.39%)
Updated Aug 15, 2026, 8:21 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AIMD closed at $1.42 after 21 trading sessions, down 13.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $1.44 | $1.555 | $1.40 | $1.42 | 21.19K |
| Aug 13, 2026 | $1.495 | $1.51 | $1.42 | $1.44 | 14.39K |
| Aug 12, 2026 | $1.51 | $1.54 | $1.45 | $1.49 | 42.63K |
| Aug 11, 2026 | $1.46 | $1.4999 | $1.45 | $1.48 | 12.04K |
| Aug 10, 2026 | $1.55 | $1.589 | $1.40 | $1.43 | 23.49K |
| Aug 7, 2026 | $1.48 | $1.557 | $1.43 | $1.49 | 34.79K |
| Aug 6, 2026 | $1.37 | $1.59 | $1.37 | $1.53 | 98.93K |
| Aug 5, 2026 | $1.36 | $1.46 | $1.35 | $1.42 | 22.34K |
| Aug 4, 2026 | $1.49 | $1.53 | $1.31 | $1.41 | 199.68K |
| Aug 3, 2026 | $1.36 | $1.48 | $1.33 | $1.45 | 3.42M |
| Jul 31, 2026 | $1.38 | $1.415 | $1.33 | $1.33 | 19.35K |
| Jul 30, 2026 | $1.36 | $1.39 | $1.30 | $1.36 | 17.66K |
| Jul 29, 2026 | $1.30 | $1.4152 | $1.30 | $1.32 | 15.76K |
| Jul 28, 2026 | $1.34 | $1.45 | $1.30 | $1.31 | 17.99K |
| Jul 27, 2026 | $1.42 | $1.455 | $1.32 | $1.33 | 58.76K |
| Jul 24, 2026 | $1.51 | $1.565 | $1.38 | $1.40 | 39.46K |
| Jul 23, 2026 | $1.6157 | $1.6157 | $1.51 | $1.51 | 14.67K |
| Jul 22, 2026 | $1.59 | $1.6201 | $1.523 | $1.54 | 19.45K |
| Jul 21, 2026 | $1.67 | $1.67 | $1.52 | $1.56 | 36.57K |
| Jul 20, 2026 | $1.6125 | $1.6993 | $1.56 | $1.59 | 26.09K |
| Jul 17, 2026 | $1.73 | $1.73 | $1.60 | $1.65 | 68.54K |
The latest Smart Investors Daily articles mentioning AIMD.
AIMD research
Company profile and research snapshot.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data Flywheel and Chemical
Benzinga · Aug 3, 2026
Ainos (NASDAQ:AIMD) reported quarterly losses of $(0.62) per share. This is a 37.37 percent increase over losses of $(0.99) per share from the same period last year. The company reported $152.000 thousand in sales this
Benzinga · Jun 22, 2026
Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a new update
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AIMD.
